01 Increasing Use of Multimodal Imaging for Myocardial Infarction Assessment The myocardial infarction market is increasingly incorporating complementary imaging techniques to determine the underlying cause, extent, and consequences of myocardial injury. Cardiac magnetic resonance, echocardiography, coronary CT angiography, and invasive coronary imaging are being used alongside clinical assessment and biomarkers to improve characterization of myocardial infarction. This is shifting clinical practice toward more comprehensive anatomical and functional assessment rather than relying on a single diagnostic measurement. In August 2026, the ESC, ACC, AHA, and WHF released the Fifth Universal Definition of Myocardial Infarction, incorporating cardiac and coronary imaging into the evaluation of myocardial infarction and encouraging imaging to help define its underlying aetiology.
02 Growing Emphasis on Personalized Secondary Prevention and Cardiac Rehabilitation Post-myocardial-infarction care is increasingly emphasizing individualized secondary prevention and structured cardiac rehabilitation to reduce recurrent cardiovascular events and improve long-term recovery. Treatment programs are being tailored around medication adherence, exercise, lifestyle modification, risk-factor management, and patient-specific rehabilitation needs. This represents a shift in the myocardial infarction care pathway from acute hospital treatment toward longer-term management of cardiovascular risk and functional recovery. In August 2026, the European Society of Cardiology released its first dedicated cardiac rehabilitation guidelines, reinforcing structured rehabilitation as an important component of cardiovascular recovery and long-term management.
01 Rising Burden of Cardiovascular Risk Factors and Coronary Disease The myocardial infarction market is supported by the continuing burden of coronary artery disease and associated risk factors such as hypertension, diabetes, obesity, smoking, and dyslipidemia. These conditions increase the population at risk of acute coronary events and sustain demand for diagnostic testing, emergency treatment, revascularization, and secondary prevention. An aging population and increasing prevalence of multiple cardiovascular risk factors further expand the need for myocardial infarction management.
01 High Cost and Unequal Access to Advanced Acute Cardiac Care Myocardial infarction treatment can require emergency hospitalization, cardiac catheterization, PCI, intensive monitoring, and long-term medication, creating substantial healthcare expenditure. Access to advanced cardiac facilities and specialist teams remains uneven across regions, particularly where emergency transport and catheterization infrastructure are limited. These differences can delay definitive treatment and restrict the adoption of advanced interventions in lower-resource healthcare systems.
01 Expansion of Remote Cardiac Rehabilitation and Post-Discharge Monitoring Remote cardiac rehabilitation and digital follow-up create opportunities to extend myocardial infarction care beyond hospital-based programs. Home-based rehabilitation can combine remote monitoring, individualized exercise programs, medication support, and clinical follow-up, potentially improving participation among patients who face geographic or mobility barriers. This opportunity is focused on post-discharge care delivery rather than AI-based diagnosis or acute diagnostic technologies.
01 Reducing Treatment Delays Across the Acute Care Pathway Rapid recognition and treatment remain challenging because myocardial infarction requires coordination among emergency services, diagnostic teams, cardiologists, catheterization laboratories, and hospital systems. Delays can occur between symptom onset, emergency presentation, diagnostic confirmation, risk assessment, and revascularization. Maintaining rapid and coordinated care is particularly difficult when patients present atypically or when healthcare systems have limited specialist and interventional capacity.
June 2026 Abbott received FDA approval for its next-generation CardioMEMS™ HERO remote monitoring reader, strengthening its cardiovascular disease management portfolio. The technology supports improved monitoring of patients with heart failure by enabling easier transmission of pulmonary artery pressure readings to healthcare providers. The advancement reflects Abbott’s continued focus on connected cardiac care solutions that support patients at risk of severe cardiovascular complications, including those with previous myocardial infarction-related conditions.
May 2026 Medtronic presented new clinical data on its cardiac rhythm management technologies, including advancements in catheter-based therapies for patients with ventricular arrhythmias following myocardial infarction. The company highlighted developments involving its Affera mapping and ablation platform with Sphere-9 catheter technology, supporting research into improved treatment approaches for post-heart attack rhythm complications.
April 2026 Abbott expanded its cardiovascular innovation initiatives by advancing integrated cardiac monitoring and intervention solutions. The company continued strengthening its portfolio across structural heart, electrophysiology, and remote monitoring technologies to support earlier detection and management of cardiovascular events associated with myocardial infarction.
March 2026 Boston Scientific continued expanding its interventional cardiology portfolio through advancements in coronary intervention technologies. The company focused on improving catheter-based treatment solutions used during coronary procedures, including technologies supporting patients requiring intervention after acute coronary events.